NIH R01 · 2024
Rational design and efficacy testing of vaccines against HCV
Project Summary An estimated 58 million people worldwide are infected with hepatitis C virus (HCV) and are at heightened risk for severe liver disease, including fibrosis, cirrhosis, and hepatocellular carcinoma. Although effective directly- acting antiviral treatment is available, only an HCV vaccine will help prevent infection, associated pathologies, and effectively reduce global disease burden. Cumulative evidence has shown that both B and T cell immunity contribute to the control of acute HCV infection. A major challenge is the high variability across the genome especially in the envelope E1E2 glycoproteins, the natural target of protective antibodies. An E1E2-based immunogen will need…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.